Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results from its randomized, double-blind, placebo controlled dose-ranging Phase 2b tr…
Story updates
10:10:53 PM UTC
SquawkNews
By Katherine HamiltonEvommune said its Phase 2b trial of a treatment for people with atopic dermatitis failed to meet its primary and secondary endpoints.The stock dropped 32%, to $8.95, in after-hours trading Tuesday. Through the close, it was down 24% this year.The trial was evaluating the effica…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.